Solvay stock: Q3 disruption cuts 2026 EBITDA outlook

Published on 10/29/2026 at 17:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Solvay stock faces a lower 2026 EBITDA outlook after disruption at a Saudi peroxide plant. Preliminary third-quarter figures point to the operational impact.

Operational pressure and revised outlook

The Middle East conflict and the shutdown of a peroxide plant affected Solvay's preliminary third-quarter performance.
Management is exploring contractual recovery mechanisms linked to the Sadara joint venture.
The November 4 results release will provide the next checkpoint for the revised outlook.

Solvay, BE0003470755, Illustration mit AI erstellt.

Solvay's preliminary third-quarter update, published on October 19, introduced a weaker operating outlook for 2026. In its regulated release republished by GlobeNewswire via Ritzau, the company linked the pressure to the Middle East conflict and the shutdown of its peroxide plant at the Sadara complex in Jubail, Saudi Arabia.

Preliminary quarter under pressure

Solvay reported underlying third-quarter sales of EUR 1.03 billion, underlying EBITDA of EUR 173 million and free cash flow to shareholders from continuing operations of EUR 54 million. The figures remain preliminary and were subject to completion of the quarter-end closing process.

The company estimated that the Middle East conflict reduced underlying EBITDA by approximately EUR 25 million in the quarter. The continued peroxide-plant shutdown accounted for close to EUR 15 million of that impact. Solvay said it is exploring available mitigation measures, while the joint venture framework includes mechanisms intended to recover lost profitability.

What has changed since our last report

The material addition is the revised full-year outlook. Excluding possible revenue or recovery measures from Sadara, Solvay now expects underlying EBITDA of EUR 720 million to EUR 740 million and free cash flow to shareholders from continuing operations of EUR 120 million to EUR 150 million, net of about EUR 90 million in transformation expenses.

For investors, the update changes the near-term earnings reference point rather than confirming a completed recovery. Solvay said it remains focused on its transformation, cash generation and cost-savings targets. Complete third-quarter results are scheduled for November 4.

Share price and investor context

Lang & Schwarz quoted Solvay at EUR 23.87 at 16:41 Berlin time on October 29, 2026. Against the previous Xetra close of EUR 23.58 on October 28, the difference is 1.23 percent; the comparison uses the dated Xetra reference shown by CNBC for the SOL-DE Xetra instrument and is separate from the Lang & Schwarz quote.

Compared with the EUR 23.56 Lang & Schwarz price in the own report published on October 28 at 10:46 CEST, the current quote is 1.32 percent higher. Investors can follow the real-time quote of Solvay stock.